Skip to content

Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment

Safety and Efficacy of Neuroform3TM for Intracranial Aneurysm Treatment

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00928265
Acronym
SENAT
Enrollment
116
Registered
2009-06-25
Start date
2008-07-31
Completion date
2010-12-31
Last updated
2013-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysm

Keywords

intracranial, stenting, endovascular treatment, stent-assisted coiling, cerebrovascular disease

Brief summary

This is a prospective observational multicenter registry to evaluate safety and efficacy data on Neuroform3TM stenting for treatment with endovascular coiling of wide neck aneurysms on an intent to treat basis. The objectives of this study are: 1. Assessment of morbidity-mortality at 1 month and 12-18 months following the treatment of the intracranial aneurysm with Neuroform3TM stent and endovascular coiling using the modified Rankin scale (mRS). 2. to evaluate adverse events. 3. Angiographic assessment at 12-18 months compared to the initial post-treatment assessment via the modified Raymond scale and same/better/worse scale.

Detailed description

There is an increasing perception in the Neurovascular community - supported by extensive peer-to-peer and congress communications - that stent-assisted coiling of intracranial wide neck aneurysms improves the long term angiographic outcome of treated patients.

Interventions

DEVICEEndovascular treatment of intracranial aneurysm.

Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion. Accomplishes this by providing coil support at the neck of the aneurysm

Sponsors

Stryker Neurovascular
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 year's old patient or above. * every patient suffering from an un-ruptured or ruptured aneurysm, for whom the endovascular treatment approach using the Neuroform3TM stent is considered by the therapeutic team in charge. * patient who has given his consent to participate to the study and to get his anonymized data collected

Exclusion criteria

* patient with dissecting or fusiform aneurysm * treatment of several aneurysms in the same procedure, except adjacent aneurysm treated by the same stent * severe vasospasm * aneurysm associated with an arterio-venous malformation * use of another Neuroform3TM stent * woman pregnant or nursing * patients not likely to be followed upon (living abroad) * people protected by justice (safeguard of law, supervision or trusteeship) * patient unsuitable to the anti-thrombotic and/or to anticoagulants therapies

Design outcomes

Primary

MeasureTime frameDescription
Morbidity and Mortality associated with stenting and coiling30 days and 12-18 months post procedureAssessment of morbidity and mortality at 30 days and 12-18 months post endovascular treatment of wide neck aneurysm with a Neurform 3 stent and coiling as assessed by the modified Rankin scale (mRS).

Secondary

MeasureTime frameDescription
Efficacy of the Neuroform stent for treatment of wide neck aneurysmspost procedure and at 12-18 months post procedureAssessment of the morphological results post endovascular coiling and stenting of wide neck aneurysms and assessment of anatomical stability of the treatment at 12-18 months post procedure

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026